Lana Pine

Manuel Litchman, MD, discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.

Exercise was beneficial in functional status for both patients with RA and spondyloarthritis.

Results offer important guidance for healthcare providers to develop tailored treatment strategies that align with the unique needs and preferences of individual patients.

Birthweight was significantly lower in women who were not treated with a TNF.

Gut microbiota-based treatment relieved pain for patients with fibromyalgia.

Kenneth Saag, MD, explores the clinical significance of a study demonstrating treatment with pegloticase leads to bone remodeling in patients with gout.

At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.

Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.

Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.

Compared with RA, patients with PsA had a higher diagnostic delay and a greater time between the onset of symptoms and the start of treatment.

Receiving methotrexate and leflunomide within the 3 months prior to conception was linked to an increased rate of adverse pregnancy outcomes.

Between 2009 and 2020, the number of rheumatologists increased 23%, from 4557 to 5600.

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

Judith Ng-Cashin, MD discusses Novotech's recent Rheumatoid Arthritis - Global Clinical Trial Landscape report.

Test your knowledge of the ACR's guideline for the management of gout with this quiz!

John H Stone, MD, MPH, discusses the recent clinician-authored white paper from the Alliance for Patient Access: "Addressing Access Barriers for IgG4-RD Patients.”

A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.

After propensity score matching, patients with COVID-19 were at an increased risk for AIRD when compared with both uninfected controls and influenza-infected patients.

The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.

The overall effect of psychological interventions on patients with fibromyalgia was -0.31 for depressive symptoms and -0.15 for anxiety symptoms, which were deemed statistically significant.

The rheumatology month in review highlights cognitive dysfunction in patients with fibromyalgia, explores the impact of obesity on treatment response in rheumatoid arthritis, and evaluates work-related challenges faced by patients with psoriatic arthritis.

A progressive and significant increase in the frequency of strong opioid consumers was observed over a 12-year period, increasing from 5.8% to 12.8%.

At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.

No statistically significant differences in the odds of remission at ≤12 months were observed between patients receiving adalimumab compared with other biologics.

Patients perceived WelTel as a beneficial tool for providing quality care across domains including efficiency, safety, and patient-centeredness.

Continuous improvement across all MDA domains was demonstrated over the 100-week timeframe, with approximately 70% of patients achieving near remission in swollen joint count, enthesitis, and the Psoriasis Area and Severity Index (PASI).

At the 6-month mark, between 73.2% to 78.6% of Canadian patients with psoriatic arthritis reported pain.

b/tsDMARD treatment led to a mean relative improvement of 41% for total work productivity in patients with psoriatic arthritis.

Findings provide insights into the current state of healthcare utilization for patients with gout living in South Korea.